ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "NEMISH PHARMA" (НЕМИШ ФАРМА)
This is a company preview
Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.
Summary
Министерство юстиции РКActivities
2ОКЭДПроизводство фармацевтических препаратов
Secondary
- 46462Оптовая реализация фармацевтических и медицинских товаров в рамках гарантированного объема бесплатной медицинской помощи
Contacts
Change history
Financial statements
PremiumPublic contracts
Assets
Bank accounts
Leadership
3- ОА
Ораз Айгили
Director
since 11.08.2016
Former directors
- ДАДЖАНМАГАМБЕТОВА АЙГУЛЬ УРАЗОВНА
- ОАОРАЗ АЙГИЛИ
Founders
Accreditations
Employees
Affiliated companies
PremiumDirector's involvement in other legal entities
Branches
Risks
0/17Комитет государственных доходов · Государственные закупки РК · АО ФНБ «Самрук-Казына» · АОО «НИШ»This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.
Court cases
Arrests & encumbrances
Enforcement proceedings
Certificates
Licenses
Company networks
PremiumSimilar companies
Media mentions
Company summary
ТОО "NEMISH PHARMA" (НЕМИШ ФАРМА) (BIN 160840010542) is an active legal entity in Алматы, registered in 2016 (10 years on the market). Primary activity — производство фармацевтических препаратов. Automated screening of open registries found no risk indicators for "NEMISH PHARMA". Director on record — Ораз Айгили. Data current as of September 5, 2026.
Information is aggregated from open government registries of Kazakhstan: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is indexed automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the corresponding facts. This is reference information and does not replace an official extract. Learn more about the methodology and sources — SafeDeal editorial policy.